Apraklonidin

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Apraklonidin
(IUPAC) ime
2,6-dihloro-N- (4,5-dihidro-1H-imidazol-2-il) benzen-1,4-diamin
Klinički podaci
Robne marke Iopidine
AHFS/Drugs.com Monografija
MedlinePlus a608005
Identifikatori
CAS broj 66711-21-5
ATC kod S01EA03
PubChem[1][2] 2216
DrugBank DB00964
ChemSpider[3] 2130
UNII 843CEN85DI YesY
KEGG[4] D07461 YesY
ChEBI CHEBI:2788 YesY
ChEMBL[5] CHEMBL647 YesY
Hemijski podaci
Formula C9H10Cl2N4 
Mol. masa 245,108 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Vezivanje za proteine plazme 98,7%
Poluvreme eliminacije 8 sata
Farmakoinformacioni podaci
Trudnoća ?
Pravni status Rx only
Način primene Ofthalmički rastvor

Apraklonidin (Iopidine) je simpatomimetik koji se koristi u terapiji glaukoma. On je agonist α2-adrenergičkog receptora i slab agonist alfa-1 adrenergičkog receptora.

Apraklonidin se administrira u koncentraciji od 1% za sprečavanje i tretman povišenog posthirurškog intraokularnog pritiska i 0.5% za kratkotrajnu adjunktivnu terapiju kod pacijenata na maksimalno tolerisanoj medicinskoj terapiji kojima je neohodna dodatna redirekcija intraokularnog pritiska. Jedna kap se obično dodaje jedan sat pre laserske operacije oka i još jedna kap nakon završetka procedure.

Reference[uredi - уреди | uredi kôd]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0061%28200004%2917:1%3C48::AID-YEA2%3E3.0.CO;2-H/full. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit

Literatura[uredi - уреди | uredi kôd]

  • Chen P, Chen J, Lu D, Chen Y, Hsiao C (2006). „Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients”. J Ocul Pharmacol Ther 22 (3): 182–7. DOI:10.1089/jop.2006.22.182. PMID 16808679. 
  • Aslanides l, Tsiklis N, Ozkilic E, Coskunseven E, Pallikaris l, Jankov M (2006). „The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients”. J Refract Surg 22 (6): 585–8. PMID 16805122. 
  • Koc F, Kansu T, Kavuncu S, Firat E (2006). „Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients”. J Neuroophthalmol 26 (1): 25–9. DOI:10.1097/01.wno.0000204648.79744.71. PMID 16518162. 
  • Garibaldi D, Hindman H, Grant M, Iliff N, Merbs S (2006). „Effect of 0.5% apraclonidine on ptosis in Horner syndrome”. Ophthal Plast Reconstr Surg 22 (1): 53–5. DOI:10.1097/01.iop.0000196322.05586.6a. PMID 16418668. 
  • Onal S, Gozum N, Gucukoglu A (2005). „Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification”. Ophthalmic Surg Lasers Imaging 36 (6): 457–62. PMID 16355950. 

Spoljašnje veze[uredi - уреди | uredi kôd]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).